Targeting the DCLK1 protein in liver cancer
Official title: Molecular targeting of DCLK1 signaling in hepatocellular carcinoma
Funded at Oklahoma City VA Medical Center · NIH-11212805 · Data updated 2026-11-12
This project explores whether blocking a protein called DCLK1 can slow tumor growth in people with cirrhosis or hepatocellular carcinoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma City VA Medical Center NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | October 1, 2017 |
| Project end | September 30, 2026 |
| Funding year | 2026 |
| NIH project number | 5I01BX004131-08 |
| Project ID | NIH-11212805 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with chronic liver disease, cirrhosis, or diagnosed hepatocellular carcinoma — especially those whose tumors show high DCLK1 levels — would be the most relevant candidates.
✕Less likely to help
People without liver disease, with non-hepatic cancers, or whose tumors do not express DCLK1 are unlikely to benefit from this approach.
What this research studies
Researchers are studying why the DCLK1 protein is high in damaged livers and liver cancers and how it links to an unusual β-catenin signaling pathway. They will examine human liver samples, run lab experiments in liver cancer cells, and use mouse models to see how DCLK1 affects tumor growth. The team will test genetic and drug-based ways to block DCLK1 signaling and measure effects on tumor behavior. Work is based at the Oklahoma City VA and could lead to opportunities for tissue donation or future clinical testing if results are promising.
Why it matters
Potential benefit: If successful, this could lead to new targeted treatments that slow tumor growth and improve outcomes for people with hepatocellular carcinoma.
How similar studies have gone: Targeting DCLK1 is a relatively new idea: preclinical studies in cells and animal models show promise but there are no proven DCLK1 therapies in patients yet.
Where this research is happening
-
Oklahoma City VA Medical Center
Oklahoma City, United States Active
Researchers
- Principal investigator: Houchen, Courtney Wayne — Oklahoma City VA Medical Center
- Study coordinator: Houchen, Courtney Wayne
Related research
Other NIH-funded projects on the same topics.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Adding PSMA PET/CT imaging to liver cancer care for veterans
This project tests a new PET imaging approach to help diagnose and guide treatment for liver cancer in veterans.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
Towards a blood-based test using nanophotonic exosomes to screen and diagnose liver cancer
A new blood test using tiny particles shed by liver cancer cells aims to screen for hepatocellular carcinoma earlier and more accurately.
-
Metabolic imaging to guide targeted therapy for liver cancer
A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.